# Truvada (tenofovir) kidney and bone density risks

> Why long-term TDF-based HIV medications have been linked to renal injury and bone loss.

**Canonical URL:** https://drugsmonitor.com/guides/truvada-tenofovir-kidney-bone-risks
**Last updated:** 2026-06-11

Truvada and other tenofovir disoproxil fumarate (TDF) medications are used for HIV treatment and PrEP. Long-term TDF use has been associated with proximal renal tubulopathy, decreased kidney function, and reductions in bone mineral density.

The newer formulation tenofovir alafenamide (TAF) has a better safety profile, but millions of patients were prescribed the older TDF formulation before the switch. Some have suffered permanent kidney damage or osteoporosis-like bone loss.

If you took TDF-based HIV medication and developed kidney problems, Fanconi syndrome, or bone density loss, preserve your medical records and consult with an attorney about potential claims.

---

*Educational guide from DrugsMonitor.com. Not legal advice.*